title: Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II).
abstract: OBJECTIVE
  The The Arterial Revascularization Therapies Study (ARTS)-II trial found no differences in survival or overall adverse events between sirolimus-eluting stents (SES) and the surgical arm of ARTS-I. Nevertheless, existing data suggest that patients with disease of the proximal left anterior descending artery (LAD) may derive particular benefit from coronary artery bypass grafting (CABG). We therefore analysed the clinical outcome of patients in ARTS-I and ARTS-II with proximal LAD involvement.
  
  
  METHODS
  Multicentre observational study.
  
  
  METHODS
  Forty-five European academic hospitals.
  
  
  METHODS
  Patients with multivessel coronary artery disease.
  
  
  METHODS
  Patients in ARTS-II with proximal LAD disease treated with SES (289/607, 48%) were compared with 187/600 (31%) bare metal stent patients (ARTS-I BMS) and 206/605 (34%) surgical patients (ARTS-I CABG) with proximal LAD involvement from ARTS-I.
  
  
  METHODS
  Major adverse cardiac and cerebrovascular events after 3 years.
  
  
  RESULTS
  The Arterial Revascularization Therapies study part 2 (ARTS-II) subgroup had better survival than both ARTS-I groups (ARTS-II 98.6% vs ARTS-I BMS 95.7%, p = 0.05 and vs ARTS-I CABG 94.7%, p = 0.01) and lower rates of the hard clinical composite endpoint of death or non-fatal myocardial infarction (ARTS-II 3.1% vs ARTS-I BMS 9.6%, p = 0.002 and vs ARTS-I CABG 9.7%, p = 0.002). Although the ARTS-I CABG patients had a lower need for repeat revascularisation than ARTS-II (5.3% vs 13.1%, p = 0.002), the overall composite adverse event rates (death, myocardial infarction, stroke or any repeat revascularisation) were not significantly different between the ARTS-I CABG and ARTS-II patients (15.0% vs 18.0%, p = 0.4).
  
  
  CONCLUSIONS
  SES are not inferior to CABG or bare metal stents for the treatment of patients with multivessel coronary disease including involvement of the proximal LAD.
authors.affiliation: Thoraxcenter, Ba-583, 's Gravendijkwal 230, Rotterdam 3015 CE, The Netherlands. p.w.j.c.serruys@erasmusmc.nl
authors.forename: N
authors.initials: N
authors.lastname: Kukreja
authors.forename: P W
authors.initials: PW
authors.lastname: Serruys
authors.forename: B
authors.initials: B
authors.lastname: De Bruyne
authors.forename: A
authors.initials: A
authors.lastname: Colombo
authors.forename: C
authors.initials: C
authors.lastname: Macaya
authors.forename: G
authors.initials: G
authors.lastname: Richardt
authors.forename: J
authors.initials: J
authors.lastname: Fajadet
authors.forename: C
authors.initials: C
authors.lastname: Hamm
authors.forename: D
authors.initials: D
authors.lastname: Goedhart
authors.forename: N
authors.initials: N
authors.lastname: Macours
authors.forename: H P
authors.initials: HP
authors.lastname: Stoll
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation; D001026:Coronary Artery Bypass / Q000009:adverse effects; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D011859:Radiography; D020123:Sirolimus / Q000627:therapeutic use*; D015607:Stents / Q000009:adverse effects; D020521:Stroke / Q000209:etiology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D020123:Sirolimus